RAT ANTI RITUXIMAB:HRP Antibody

835 EUR

100ug

GEN224427

N/A

N/A

N/A

N/A

N/A

IgG2a

MB2 A4

anticorps

RITUXIMAB

Monoclonal

Antibodies

ELISA (EIA)

HRP Conjugated

Rattus norvegicus

Mnoclonal antibodies

Rat (Rattus norvegicus)

IgG concentration 1.0 mg/ml

HRP (Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid)

N/A; Due to limited knowledge and inability for testing each and every species, the reactivity of the antibody may extend to other species which are not listed hereby.

This antibody needs to be stored at + 4°C in a fridge short term in a concentrated dilution. Freeze thaw will destroy a percentage in every cycle and should be avoided.

Rats are used to make rat monoclonal anti mouse antibodies. There are less rat- than mouse clones however. Rats genes from rodents of the genus Rattus norvegicus are often studied in vivo as a model of human genes in Sprague-Dawley or Wistar rats.

Keep the antibody refrigerated at +4 degrees Celsius. Temperature variations in the range between +1C to +7C are tolerable. DO NOT FREEZE. the antibody should be stored undiluted. If there is a precipitate in the vial we recommend you to briefly microcentrifugate it prior to use. Shelf Life: 18 months from date of dispatch.

If you buy Antibodies supplied by MBS Monoclonals they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.HRP conjugates are often primary rabbit polyclonal antibodies couples to the enzyme horseradish peroxidase (HRP), found in the roots of horseradish. Also monoclonal HRP conjugates are often used for Western Blot.

RITUXIMAB Anti Rituximab clone MB2 A4 specifically recognises the idiotypic determinants expressed by the Rituximab humanised monoclonal antibody. Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen. Clone MB2 A4 does not recognise other CD20 antibodies, and has been used in ELISA assays to monitor the levels of Rituximab in patient serum following therapy. This antibody has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound 'in vivo' to B-CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonised cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab; Since it is not possible to test each and every species our knowledge on the corss reactivity of the antibodies is limited. This particular antibody might cross react with speacies outside of the listed ones.